CAR T-Cell Therapy for Large B-Cell Lymphoma — Who, When, and How?
Open accessAbstract
Large B-cell lymphoma is a spectrum of aggressive B-cell cancers with broad genetic and clinical heterogeneity.1 First-line chemotherapy cures most patients, but those with relapsed or refractory disease usually die of lymphoma. Salvage chemotherapy followed by autologous stem-cell transplantation (ASCT) is the standard second-line approach to large B-cell lymphoma and cures up to 30 to 40% of eligible patients, but it is restricted to younger, fit patients and is relatively ineffective in chemotherapy-refractory disease.2 Chimeric antigen receptor (CAR) T-cell therapies that target CD19 have advanced the treatment of multiply relapsed large B-cell lymphoma and showed promising rates of durable remission . . .
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CAR-T-cell therapy offers durable remission and markedly extends survival in patients with relapsed/refractory large B-cell lymphoma.
“Chimeric antigen receptor (CAR)-T-cell therapy has emerged as a revolutionary treatment; specifically, it offers durable remission and markedly extends survival in patients with relapsed/refractory large B-cell lymphoma patients.”
From The burdens, coping strategies, and unmet needs of family caregivers of Chinese patients with lymphoma receiving commercial CAR-T-cell therapy: A qualitative study (2026) · cites this paper as [5]
The main text reports durable remission in up to 40% of multiply relapsed large B-cell lymphoma cases. It also reports superior event-free survival with CAR-T therapy in ZUMA-7, but no event-free-survival difference in BELINDA. It does not establish that CAR-T therapy markedly extends overall survival across patients with relapsed or refractory disease; page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 11 · Cited by 70
Research works printed but not linked: 8
- [1]Schmitz R, Wright GW, Huang DW, Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England journal of medicine 2018; 378(15): 1396– 1407. DOI: 10.1056/NEJMoa1801445. 29641966 PMC6010183 · DOI · Paper page
- [2]Gisselbrecht C, Glass B, Mounier N, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010; 28(27): 4184– 90. DOI: 10.1200/JCO.2010.28.1618. 20660832 PMC3664033 · DOI
- [4]Neelapu SS, Locke FL, Bartlett NL, Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England journal of medicine 2017; 377(26): 2531– 2544. DOI: 10.1056/NEJMoa1707447. 29226797 PMC5882485 · DOI · Paper page
- [6]Schuster SJ, Tam CS, Borchmann P, Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology 2021; 22(10): 1403– 1415. DOI: 10.1016/S1470-2045(21)00375-2. 34516954 · DOI
- [7]Locke FL, Ghobadi A, Jacobson CA, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. The Lancet Oncology 2019; 20(1): 31– 42. DOI: 10.1016/S1470-2045(18)30864-7. 30518502 PMC6733402 · DOI · Paper page
- [8]Bishop MR. BELINDA. The New England journal of medicine 2021.
- [9]Locke FL, Miklos DB, Jacobson C, Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Blood 2021; 138(Supplement 1): 2– 2. DOI: 10.1182/blood-2021-148039. · DOI
- [10]Pinnix CC, Gunther JR, Dabaja BS, Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 2020; 4(13): 2871– 2883. DOI: 10.1182/bloodadvances.2020001837. 32589728 PMC7362355 · DOI
- Authors
- Roschewski, M., Longo, D. L., & Wilson, W. H.
- Affiliations
- National Institutes of Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-02-17
- Volume
- 386
- Issue
- 7
- Pages
- 692-696
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9295142
- OpenAlex
- W4200302294
- Cited by
- 70
- References
- 11
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 16 · 2023: 23 · 2022: 18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (Z99 CA999999)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, large B-cell lymphoma, CD19, relapsed/refractory lymphoma, autologous stem cell transplantation, salvage chemotherapy, sustained remission, treatment selection
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
